By Fineline Cube 
China’s National Medical Products Administration (NMPA) has approved Innovent Biologics, Inc.’s (HKG: 1801) mazdutide (IBI362), a dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist co-developed with Eli Lilly and Company (NYSE: LLY). The drug is now approved for long-term weight management in adult patients with an initial Body Mass Index (BMI) of ≥28 kg/m² (obesity) or BMI ≥24 kg/m² (overweight) accompanied by at least one weight-related comorbidity.
Clinical Profile
Mazdutide has demonstrated significant weight reduction effects in overweight or obese subjects, along with improvements in waist circumference, systolic blood pressure, triglycerides, cholesterol, and other metabolic parameters.
Regulatory Status
The drug is currently under review in China for the treatment of type 2 diabetes (T2D).-Fineline Info & Tech